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KEY MESSAGES
  The ‘public’ in public engagement could be a variety of stakeholders.
  Engaging with the public builds trust and helps to identify concerns that need to be addressed.
  There is a need for more research on the impact of different public engagement strategies on vaccination programmes to
improve their effectiveness.
The importance of listening to and engaging publics in the
design and implementation of immunization policies and
programmes has been well established (Waisbord 2004;
Cooper et al. 2008; Obregon 2009; Larson et al. 2010; Larson
et al. 2011). There are a number of examples of the costs
(financial and social) of not involving publics early, the most
acute being the boycott of polio vaccination in five states in
Northern Nigeria in 2003 (Yahya 2007).
Several papers in this special issue highlight potential roles of
publics in the introduction of new vaccines, mostly at the level of
implementation, but some pointto the importance of bringing the
role of citizen voices earlier into the decision-making process—i.e.
not just as players to implement decisions made by central
authorities, but to be a part of decision-making processes
(Wonodi et al. 2012).
The ‘public’ in public engagement could be a variety of
stakeholders; such as individuals, parents, policy-makers
(Mantel and Wang 2012), researchers and clinicians (Burchett
et al. 2012), immunization programme managers (Brooks and
Ba-Nguz 2012; Gordon et al. 2012), ‘global/regional bodies’
(Makinen et al. 2012), advocacy groups, or influential individ-
uals (Makinen et al. 2012), such as religious leaders (Wonodi
et al. 2012).
The social network analysis around new vaccine introduction
in Nigeria recognized that ‘vaccine programmes can benefit
from engaging religious leaders in discussions about the needs
of their community and how best to meet them’ (Wonodi et al.
2012). The polio boycott in Northern Nigeria in 2003 high-
lighted the importance of religious leaders in influencing
parents, first negatively and then positively towards the polio
vaccine.
There are several different ways of engaging publics, from
town hall meetings and focus groups to hotlines, consultations
and social mobilization activities (Wonodi et al. 2012), and
engaging with religious leaders. Effective public engagement
strategies in the polio eradication effort in India contributed to
the success, resulting in no polio transmission in over one year
since January 2011 (GPEI 2011). Public engagement is not a
communications campaign informing the public when to get
their vaccines (which is also needed); it is about dialogue with
stakeholders and about trust building (see Box 1).
During the introduction of a new vaccine, it is important to
engage with the public early on, during the planning stages, in
order to anticipate and to identify any potential concerns or
issues as well as opportunities. Public engagement should also
be carried out throughout the implementation of vaccination
programmes to stay alert to any emerging concerns as well as to
sustain the support of the public.
The ‘public’ are a broad population with a considerable
amount of diversity. We need to understand this diversity and
to listen to the views and perceptions of the different sections
of the public. We also need to engage with the public as
advocates and as implementers and to respond to any concerns
as they arise.
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on vaccination programmes. In order to carry out effective
public engagement, it is important to understand contextual
factors and to understand what is driving public questions and
the specific concerns around vaccines and/or vaccination
programmes.
At the London School of Hygiene and Tropical Medicine, we
lead a team developing a surveillance system to detect and
investigate public concerns about vaccines early in order to
identify underlying issues and contextual factors that need to
be addressed. This research has emerged following the evidence
that public questioning and public concerns can and have led to
vaccine refusals, interruptions or suspensions of vaccine
programmes, and to consequent vaccine-preventable disease
outbreaks.
Examples of when publics have recently challenged vaccines
and policies include the suspension of the HPV vaccine
demonstration projects in India in 2010 (Sinha 2010), the
suspension of H1N1 vaccine in Finland in August 2010 (THL
2010), and the challenges to introducing Hib vaccine in India
(Mudur 2010).
In India there was questioning around the introduction of the
HPV vaccine, when cervical screening and more ‘needed’ less
expensive vaccines were still not universally available (Larson
et al. 2010). An HPV vaccine demonstration project in India was
suspended in 2010 in response to recurrent and increasing
demands from advocacy groups about a number of concerns
(Larson et al. 2010; PATH 2010; Sinha 2010).
In another instance, as a reaction to public concerns in
Finland about a possible associated link with narcolepsy, the
National Institute for Health and Welfare recommended that
vaccination with the H1N1 vaccine Pandemrix be discontinued
in August 2010 until an explanation was found (THL 2010).
Pandemrix was later re-introduced with the recommendation
by the European Medicines Agency and the Committee for
Medicinal Products for Human Use (CHMP) to restrict its use.
In India, a barrier to the introduction of the Hib vaccine was
conflicting views on whether the disease burden in India
merited the introduction of the Hib vaccine, especially in light
of its cost, while other, more affordable and universally needed
vaccines were not available (Mudur 2010).
The lessons that have been learnt around the importance of
early public engagement and dialogue should be applied to the
introduction of all new vaccines, as well as to sustain the
acceptance of already available vaccines. For example, early
public engagement and dialogue could arguably have assisted
the polio eradication effort and possibly mitigated the vaccine
boycott in Nigeria in 2003. Also, timely government response
to public appeals for an open forum on the HPV vaccine
project in India could potentially have avoided the public
pressures that resulted in the government having to suspend
the project.
Pneumococcal vaccine is being introduced in several coun-
tries, including Central African Republic, Benin, Cameroon and
Ethiopia. Meningococcal vaccine is being introduced in Ghana,
Benin, Senegal, and HPV vaccine in Rwanda, Macedonia and
Tajikistan amongst other countries. With donor support, GAVI
plans to introduce rotavirus vaccine in over 40 countries by
2015. Theses vaccines are being introduced at an accelerated
pace. Although each of these vaccines can help in the fight
against infectious diseases and save thousands of lives, without
the genuine engagement of publics through all phases of
introduction, their true benefits will never be fully realized.
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pre-empt breakdowns in public confidence
  Engaging the public as advocates for immuniza-
tion and to support the implementation of vaccine
programmes
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